Continuous Manufacturing Market (Small Molecules and Biologics), 2020-2030"
Roots Analysis has announced the addition of "Continuous Manufacturing Market (Small Molecules and Biologics), 2020-2030" report to its list of offerings.
By: Roots Analysis
Key Market Insights
Around 65 companies claim to have expertise in continuous manufacturing of small molecule / biologic drugs
The continuous manufacturing market landscape is dominated by well-established players (founded before 1990), which represent more than 50% of the total number of stakeholders. Amongst these, close to 55% players are headquartered in Europe, followed by those based in North America (36%).
Close to 45 partnerships were inked between 2013 and 2019
More than 55% of such agreements were focused on technology improvements and research. Further, 58% of the recent partnerships were established for drug product manufacturing, while the remaining were focused on the production of API / intermediate.
Nearly 55 expansion initiatives were undertaken in the period 2013-2020 (till January)
Most such projects (55%) were reported to be focused on establishment of a new facility / plant, followed by those carried out for incorporating continuous manufacturing technologies (28%) into the existing facilities of different companies. It is worth mentioning that more than 45% of the total number of expansions captured in the report, were observed to have been carried out in Europe.
Around 165 grants were awarded to support ongoing R&D activities in continuous manufacturing, between 2014 and 2019
Collectively, the capital amount awarded to support R&D in this field was estimated to be worth USD 69.7 million. It is worth noting that 35 grants were awarded in 2019 alone. A significant proportion of grants identified in the report (22%) were awarded to the Illinois Institute of Technology, followed by those awarded to Purdue University (12%).
Several patents have been filed / granted related to continuous manufacturing
It is worth noting that majority of patents (187) were filed / granted in 2019; of these, close to 75% represented the intellectual capital of industry players. Further, around 50% of the total number of patents were filed / granted in North America, followed by Europe (35%).
Over 70% of the installed continuous manufacturing capacity belongs to established players
For additional details, please visit
+1 (415) 800 3415
+44 (122) 391 1091